Skip to main content
Premium Trial:

Request an Annual Quote

IonPath: Sander Gubbens

IonPath has appointed Sander Gubbens as CEO. He replaces company cofounder Harris Fienberg.

Gubbens was most recently president of Gatan, a cryo-electron microscopy firm, which was acquired by Amtek in 2019 for $925 million. He has over 30 years of experience in developing and commercializing technology in the life science, materials science, and semiconductor industries. Prior to Gatan, he held senior R&D roles at KLA-Tencor.

An inventor on 17 patents and a member of the board of PCR instrument maker Combinati, Gubbens holds a doctorate in applied physics from The Netherlands' Delft University of Technology and an MBA from the University of California, Berkeley Hass School of Business.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.